Limits...
Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion

View Article: PubMed Central - PubMed

ABSTRACT

The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).

Twenty-four patients with non–small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m2) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume. Pharmacokinetic (PK) profile and urinary excretion rate of paclitaxel were analyzed with serum vascular endothelial growth factor (VEGF) level, and adverse events were examined as well.

The combination therapy reduced the MPE level with a successful rate of 29% and a survival rate of 25% over the single paclitaxel treatment in the study cohort (both P < 0.05). PKs for the combined treatment displayed a rapid distribution of the anticancer drug paclitaxel with an obvious increase in its elimination half-life in the pleural fluid (both P < 0.01). Mean residence time of paclitaxel increased in the presence of Avastin (P < 0.01). Serum VEGF levels significantly reduced in the Avastin-treated patients as compared to the paclitaxel-treated ones (P < 0.01). The urinary excretion rate was similar in the study cohort. Incidence of adverse events for the 2 treatment approaches was similar in the patients.

Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues.

No MeSH data available.


Related in: MedlinePlus

Adverse events by 2 treatment approaches. Side effects for the paclitaxel treatment were observed in presence (n = 14) and absence (n = 10) of Avastin. Most common adverse events for each treatment response are expressed with a percentage of the positive population proportion in the study cohort. A χ2 test showed a P value >0.05 between the 2 treatment approaches.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5134869&req=5

Figure 6: Adverse events by 2 treatment approaches. Side effects for the paclitaxel treatment were observed in presence (n = 14) and absence (n = 10) of Avastin. Most common adverse events for each treatment response are expressed with a percentage of the positive population proportion in the study cohort. A χ2 test showed a P value >0.05 between the 2 treatment approaches.

Mentions: Adverse events for the paclitaxel treatment were examined in presence (n = 14) and absence (n = 10) of Avastin according to CTCAE v3.0, which is a descriptive terminology utilized for adverse event reporting. Data are calculated with a percentage of a population proportion for each treatment response, and the results are shown in Fig. 6. The most common adverse events included chest pain, low blood counts (red white cells and platelets), nausea/vomiting, diarrhea, and bleeding during the period of treatment. Severity of the side effects generally presented in a range of the grades 1 to 2. In contrast, the symptoms of low white blood cells, nausea/vomiting, and chest pain constituted a relatively large proportion in the study cohort with 50%, 38%, and 37% in the paclitaxel-treated patients and 50%, 50%, and 20% in the paclitaxel/Avastin-treated ones, respectively. However, incidence (%) of the adverse effects was not obviously different in the patients who experienced the 2 treatment methods.


Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
Adverse events by 2 treatment approaches. Side effects for the paclitaxel treatment were observed in presence (n = 14) and absence (n = 10) of Avastin. Most common adverse events for each treatment response are expressed with a percentage of the positive population proportion in the study cohort. A χ2 test showed a P value >0.05 between the 2 treatment approaches.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5134869&req=5

Figure 6: Adverse events by 2 treatment approaches. Side effects for the paclitaxel treatment were observed in presence (n = 14) and absence (n = 10) of Avastin. Most common adverse events for each treatment response are expressed with a percentage of the positive population proportion in the study cohort. A χ2 test showed a P value >0.05 between the 2 treatment approaches.
Mentions: Adverse events for the paclitaxel treatment were examined in presence (n = 14) and absence (n = 10) of Avastin according to CTCAE v3.0, which is a descriptive terminology utilized for adverse event reporting. Data are calculated with a percentage of a population proportion for each treatment response, and the results are shown in Fig. 6. The most common adverse events included chest pain, low blood counts (red white cells and platelets), nausea/vomiting, diarrhea, and bleeding during the period of treatment. Severity of the side effects generally presented in a range of the grades 1 to 2. In contrast, the symptoms of low white blood cells, nausea/vomiting, and chest pain constituted a relatively large proportion in the study cohort with 50%, 38%, and 37% in the paclitaxel-treated patients and 50%, 50%, and 20% in the paclitaxel/Avastin-treated ones, respectively. However, incidence (%) of the adverse effects was not obviously different in the patients who experienced the 2 treatment methods.

View Article: PubMed Central - PubMed

ABSTRACT

The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs).

Twenty-four patients with non–small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m2) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume. Pharmacokinetic (PK) profile and urinary excretion rate of paclitaxel were analyzed with serum vascular endothelial growth factor (VEGF) level, and adverse events were examined as well.

The combination therapy reduced the MPE level with a successful rate of 29% and a survival rate of 25% over the single paclitaxel treatment in the study cohort (both P < 0.05). PKs for the combined treatment displayed a rapid distribution of the anticancer drug paclitaxel with an obvious increase in its elimination half-life in the pleural fluid (both P < 0.01). Mean residence time of paclitaxel increased in the presence of Avastin (P < 0.01). Serum VEGF levels significantly reduced in the Avastin-treated patients as compared to the paclitaxel-treated ones (P < 0.01). The urinary excretion rate was similar in the study cohort. Incidence of adverse events for the 2 treatment approaches was similar in the patients.

Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues.

No MeSH data available.


Related in: MedlinePlus